SynthesisFrontiers in nutrition2026
Tea and liver fibrosis: a bibliometric analysis of mechanisms, translational challenges, and emerging trends.
Synthesis in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Although tea and its bioactive constituents, particularly epigallocatechin gallate (EGCG), demonstrate promising anti-liver fibrotic potential, the global research landscape has yet to be systematically characterized through quantitative visualization, leaving research priorities and clinical translational barriers unclear. This bibliometric analysis aims to delineate the current status, emerging hotspots, and developmental trends in tea-related liver fibrosis research, providing strategic insights for future studies. Methods: A dual-database search with reciprocal verification was conducted in the Web of Science Core Collection (WoSCC) and Scopus using refined search strategies. Bibliometric analyses and visualizations were performed using R (v4.5.1), VOSviewer (v1.6.19), and CiteSpace (v6.4.R1). Results: Annual publication output in this field has increased steadily. China led in publications ( Conclusion: This study elucidates the therapeutic potential of tea and its bioactive constituents against liver fibrosis, encompassing their pharmacological mechanisms, emerging molecular targets, and bioavailability enhancement strategies. With advances in nanomedicine and pharmaceutical technologies, coupled with rigorously designed multicenter randomized controlled trials, tea-derived bioactives are anticipated to overcome current limitations and establish clinical value in liver fibrosis prevention and adjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.